GDTC

+ Watchlist + Portfolio

CytoMed Therapeutics Limited

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.90
52-Week Range: $0.68 – $3.68
Market Cap: $10.98M
P/E (TTM): —
EPS (TTM): -0.23
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 2.80
PEG Ratio: —
Return on Equity: -56.17%
Return on Assets: -32.52%
Gross Margin: 85.89%
Operating Margin: -476.09%
Profit Margin: 0.00%
Current Ratio: 2.64
Debt/Equity: 0.08
Total Debt: $454.13K
Free Cash Flow: $-2.37M
Revenue Growth: -15.90%
Earnings Growth: —
Enterprise Value: $10.40M

GDTC Income statement, annual periods, in SGD
SGD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$69.50K	$324.39K
Cost of Revenue	$0.00	$0.00	$17.12K	$67.99K
Gross Profit	$0.00	$0.00	$52.38K	$256.39K
Research & Development	$1.52M	$1.59M	$1.91M	$2.22M
Selling, General & Admin	$397.11K	$1.28M	$1.27M	$1.84M
Operating Expenses	$1.86M	$3.84M	$3.18M	$4.50M
Operating Income	-$1.86M	-$3.84M	-$3.13M	-$4.24M
EBITDA	-$2.61M	-$3.70M	-$2.17M	-$3.57M
Pretax Income	-$3.13M	-$4.13M	-$2.52M	-$4.00M
Income Tax	$1.64K	$653.00	$0.00	$0.00
Net Income	-$3.13M	-$4.13M	-$2.52M	-$3.98M
Diluted EPS	-0.29	-0.39	—	—
Diluted Shares	10.94M	10.63M	—	—

GDTC Balance Sheet statement, annual periods, in SGD
SGD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$1.58M	$9.00M	$4.97M	$2.10M
Receivables	$57.58K	$204.75K	$121.21K	$132.05K
Current Assets	$2.49M	$10.10M	$6.00M	$3.66M
Total Assets	$5.23M	$12.37M	$10.07M	$7.98M
Current Liabilities	$4.17M	$716.94K	$606.62K	$709.17K
Long-Term Debt	$468.83K	$407.77K	$394.31K	$368.66K
Total Debt	$4.22M	$448.02K	$463.25K	$482.56K
Total Liabilities	$4.64M	$1.12M	$1.02M	$1.13M
Retained Earnings	-$8.20M	-$12.33M	-$14.85M	-$18.83M
Shareholders' Equity	$586.98K	$11.25M	$8.97M	$6.54M
Working Capital	-$1.67M	$9.38M	$5.39M	$2.95M
Net Debt	$2.63M	—	—	—

GDTC Cash Flow statement, annual periods, in SGD
SGD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.40M	-$3.53M	-$2.71M	-$3.70M
Capital Expenditure	-$473.80K	-$58.30K	-$1.49M	-$703.13K
Free Cash Flow	-$1.87M	-$3.59M	-$4.20M	-$4.40M
Depreciation & Amortisation	$392.87K	$381.15K	$335.36K	$401.58K
Stock-Based Compensation	—	$0.00	$0.00	$694.20K
Investing Cash Flow	-$473.31K	-$2.73M	$1.13M	$929.28K
Financing Cash Flow	$968.72K	$10.92M	-$64.89K	$208.65K
Dividends Paid	$0.00	$0.00	$0.00	$0.00
Net Change in Cash	-$903.00K	$4.66M	-$1.65M	-$2.56M

GDTC Balance Sheet statement, quarterly periods, in SGD
SGD	Q4 2024	Q4 2025
Cash & Equivalents	$4.97M	$2.10M
Receivables	$121.21K	$132.05K
Current Assets	$6.00M	$3.66M
Total Assets	$10.07M	$7.98M
Current Liabilities	$606.62K	$709.17K
Long-Term Debt	$394.31K	$368.66K
Total Debt	$463.25K	$482.56K
Total Liabilities	$1.02M	$1.13M
Retained Earnings	-$14.85M	-$18.83M
Shareholders' Equity	$8.97M	$6.54M
Working Capital	$5.39M	$2.95M

Market Snapshot

About

CytoMed Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing cell-based immunotherapies for cancer treatment. The company specializes in gamma-delta T cell therapies, a unique approach to harnessing the immune system to target cancer cells. CytoMed's proprietary platform enables the development of allogeneic (off-the-shelf) cell therapies that can be administered to multiple patients without the need for patient-specific customization. The company's pipeline includes therapeutic candidates targeting various hematologic and solid tumor malignancies. CytoMed conducts clinical trials to evaluate the safety and efficacy of its investigational therapies in cancer patients.